News

Impax’s generic division Global Pharmaceuticals is expected to launch the product. Impax claimed that the FDA awarded the company 180 days of generic drug exclusivity as it was

As per the terms of the agreement, Eisai is expected to have non-exclusive access to Forma’s Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to

As per the terms of the agreement, Zydus will market ABI’s dietary supplement Maxisal in India and Nepal. Maxisal enhances salivary function, promotes oral comfort and helps relieve

Amylin said that the study will be conducted by researchers at The University of Texas (UT) Southwestern Medical Cente. Prior studies at UT Southwestern conducted in animal models

Aoxing Pharma has posted a net loss of $653,939 for the first quarter 2010, or $0.01 loss per diluted share, compared to $2.29m, or $0.05 loss per diluted

DoseEdge is the pharmacy workflow management tool that verifies the use of correct drugs, diluents and concentrations in the compounding of IV, chemo, TPN and oral liquid doses.

Intelleflex claimed that the new HMR-9090 Handheld Reader and FMR-6000 Fixed Reader work with the company’s tags to enable wireless, on-demand, product-level monitoring by providing the ability to

Advanced Proteome Therapeutics (APC) has entered into an agreement for a feasibility study with a global pharmaceutical company interested in evaluating APC’s proprietary crosslinking technologies. As per the

Clinical Data said that the issued patent, which will expire in June 2022, covers Vilazodone HC1 in Form IV, its process of preparation and method of treatment therewith.